TrialCancer2019

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Suman Malempati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.